The Cooper Companies, Inc. (COO) 10-Q 1 Sep 17 2017 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information	9 Months Ended
	Jul. 31, 2017shares
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jul. 31, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q3
Entity Registrant Name	COOPER COMPANIES INC
Entity Central Index Key	711,404
Current Fiscal Year End Date	--10-31
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding	48,949,240

Consolidated Statements of Inco

Consolidated Statements of Income - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Jul. 31, 2017	Jul. 31, 2016	Jul. 31, 2017	Jul. 31, 2016
Income Statement [Abstract]
Net sales	$ 556,000	$ 514,700	$ 1,577,500	$ 1,448,200
Cost of sales	199,800	198,100	565,100	571,100
Gross profit	356,200	316,600	1,012,400	877,100
Selling, general and administrative expense	208,700	182,400	590,600	533,700
Research and development expense	17,500	15,900	50,600	47,400
Amortization of intangibles	17,200	15,600	50,600	46,100
Operating income	112,800	102,700	320,600	249,900
Interest expense	8,300	8,000	23,300	20,900
Other (income) expense, net	(3,200)	1,300	(100)	2,200
Income before income taxes	107,700	93,400	297,400	226,800
Provision for income taxes	4,100	5,200	13,100	12,400
Net income	103,600	88,200	284,300	214,400
Less: net income attributable to noncontrolling interests	0	300	0	1,000
Net income attributable to Cooper stockholders	$ 103,600	$ 87,900	$ 284,300	$ 213,400
Earnings per share attributable to Cooper stockholders - basic (in dollars per share)	$ 2.12	$ 1.81	$ 5.81	$ 4.41
Earnings per share attributable to Cooper stockholders - diluted (in dollars per share)	$ 2.09	$ 1.79	$ 5.74	$ 4.36
Number of shares used to compute earnings per share:
Basic (shares)	48,900	48,600	48,900	48,400
Diluted (shares)	49,600	49,000	49,500	48,900

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income (Loss) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Jul. 31, 2017	Jul. 31, 2016	Jul. 31, 2017	Jul. 31, 2016
Statement of Comprehensive Income [Abstract]
Net income	$ 103.6	$ 88.2	$ 284.3	$ 214.4
Other comprehensive income (loss):
Foreign currency translation adjustment	38.3	(126.8)	104.8	(188.3)
Comprehensive income (loss)	141.9	(38.6)	389.1	26.1
Less: comprehensive income attributable to noncontrolling interests	0	0.3	0	1
Comprehensive income (loss) attributable to Cooper stockholders	$ 141.9	$ (38.9)	$ 389.1	$ 25.1

Consolidated Condensed Balance

Consolidated Condensed Balance Sheets - USD ($) $ in Millions	Jul. 31, 2017	Oct. 31, 2016
Current assets:
Cash and cash equivalents	$ 46	$ 100.8
Trade accounts receivable, net of allowance for doubtful accounts of $10.0 at July 31, 2017 and $8.5 at October 31, 2016	335.9	291.4
Inventories	453.9	417.7
Deferred tax assets (1)	0	49.7
Prepaid expense and other current assets	96.3	77.5
Total current assets	932.1	937.1
Property, plant and equipment, at cost	1,718.5	1,603.2
Less: accumulated depreciation and amortization	823.6	725.5
Property, plant and equipment, net	894.9	877.7
Goodwill	2,333.6	2,164.7
Other intangibles, net	487.9	441.1
Deferred tax assets (1)	66.1	6.1
Other assets	68.2	51.9
Total assets	4,782.8	4,478.6
Current liabilities:
Short-term debt	33.4	226.3
Accounts payable	112.2	107.4
Employee compensation and benefits	75.5	77.7
Other current liabilities	150.1	131.8
Total current liabilities	371.2	543.2
Long-term debt	1,180	1,107.4
Deferred tax liabilities (1)	30.9	37.5
Accrued pension liability and other	107.4	94.6
Total liabilities	1,689.5	1,782.7
Commitments and contingencies
Stockholders’ equity:
Preferred stock, 10 cents par value, shares authorized: 1.0; zero shares issued or outstanding	0	0
Common stock, 10 cents par value, shares authorized: 120.0; issued 52.4 at July 31, 2017 and 52.1 at October 31, 2016	5.2	5.2
Additional paid-in capital	1,516.9	1,494
Accumulated other comprehensive loss	(384.8)	(489.6)
Retained earnings	2,345.6	2,046.3
Treasury stock at cost: 3.4 shares at July 31, 2017 and 3.3 shares at October 31, 2016	(389.7)	(360.1)
Noncontrolling interests	0.1	0.1
Stockholders’ equity	3,093.3	2,695.9
Total liabilities and stockholders' equity	$ 4,782.8	$ 4,478.6

Consolidated Condensed Balance5

Consolidated Condensed Balance Sheets (Parenthetical) - USD ($) $ in Millions	Jul. 31, 2017	Oct. 31, 2016
Statement of Financial Position [Abstract]
Trade accounts receivable, allowance for doubtful accounts	$ 10	$ 8.5
Preferred stock, par value	$ 0.1	$ 0.1
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.1	$ 0.1
Common stock, shares authorized	120,000,000	120,000,000
Common stock, shares issued	52,400,000	52,100,000
Treasury stock, shares	3,400,000	3,300,000

Consolidated Condensed Statemen

Consolidated Condensed Statements of Cash Flows - USD ($) $ in Millions	9 Months Ended
	Jul. 31, 2017	Jul. 31, 2016
Cash flows from operating activities:
Net income	$ 284.3	$ 214.4
Depreciation and amortization	141.2	150.9
Decrease in operating capital	(58.7)	(54.6)
Other non-cash items	27.8	5.6
Net cash provided by operating activities	394.6	316.3
Cash flows from investing activities:
Purchases of property, plant and equipment	(95.4)	(117.4)
Acquisitions of businesses, net of cash acquired, and other	(197)	(251.3)
Net cash used in investing activities	(292.4)	(368.7)
Cash flows from financing activities:
Proceeds from long-term debt	1,064.8	1,514.3
Repayments of long-term debt	(984.6)	(1,397.4)
Net repayments of short-term debt	(202.3)	(23)
Repurchase of common stock	(29.5)	0
Net (payments) proceeds related to share-based compensation awards	(5.6)	6.2
Excess tax benefit from share-based compensation awards (1)	0	11.8
Dividends on common stock	(1.5)	(1.5)
Debt acquisition costs	0	(12.5)
Distributions to noncontrolling interests	0	(0.7)
Payment of contingent consideration	(4.3)	0
Proceeds from construction allowance	2.1	4.3
Net cash (used in) provided by financing activities	(160.9)	101.5
Effect of exchange rate changes on cash and cash equivalents	3.9	(2.9)
Net (decrease) increase in cash and cash equivalents	(54.8)	46.2
Cash and cash equivalents - beginning of period	100.8	16.4
Cash and cash equivalents - end of period	$ 46	$ 62.6

General

General	9 Months Ended
	Jul. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
General	General The Cooper Companies, Inc. (Cooper, we or the Company) is a global medical device company publicly traded on the NYSE Euronext (NYSE: COO). Cooper is dedicated to being A Quality of Life Company TM with a focus on delivering shareholder value. Cooper operates through our business units, CooperVision and CooperSurgical. • CooperVision primarily develops, manufactures and markets a broad range of soft contact lenses for the worldwide vision correction market. • CooperSurgical primarily develops, manufactures, markets medical devices and procedures solutions, and provides services to improve health care delivery to families. The unaudited consolidated condensed financial statements presented in this report contain all adjustments necessary to present fairly Cooper’s consolidated condensed financial position at July 31, 2017 and October 31, 2016 , the consolidated results of its operations for the three and nine months ended July 31, 2017 and 2016 and its consolidated condensed cash flows for the nine months ended July 31, 2017 and 2016 . Most of these adjustments are normal and recurring. However, certain adjustments associated with acquisitions are of a nonrecurring nature. Readers should not assume that the results reported here either indicate or guarantee future performance. During interim periods, we follow the accounting policies described in our Annual Report on Form 10-K for the fiscal year ended October 31, 2016 . Please refer to this when reviewing this Quarterly Report on Form 10-Q. Management estimates and judgments are an integral part of financial statements prepared in accordance with accounting principles generally accepted in the United States of America (GAAP). We believe that the critical accounting policies listed below address the more significant estimates required of Management when preparing our consolidated financial statements in accordance with GAAP. We consider an accounting estimate critical if changes in the estimate may have a material impact on our financial condition or results of operations. We believe that the accounting estimates employed are appropriate and resulting balances are reasonable; however, actual results could differ from the original estimates, requiring adjustment to these balances in future periods. The accounting policies that reflect our more significant estimates, judgments and assumptions and which we believe are the most critical to aid in fully understanding and evaluating our reported financial results are: • Revenue recognition • Net realizable value of inventory • Valuation of goodwill • Business combinations • Income taxes • Share-based compensation During the first nine months of fiscal 2017 , there were no significant changes in our estimates and critical accounting policies except for the accounting pronouncements that were recently adopted which are discussed below. Please refer to Note 1. Summary of Significant Accounting Policies of our Annual Report on Form 10-K for the fiscal year ended October 31, 2016 , for a more complete discussion of our estimates and critical accounting policies. During the first quarter of fiscal 2017, the Company identified and recorded an amount of $4.1 million , net of income tax expense, to reflect a net cumulative decrease to retained earnings as of the opening balance sheet for the fiscal year ended October 31, 2016 and a corresponding net increase in other current liabilities and deferred tax asset, all associated with an understatement of accruals for rebates in prior years. Accordingly, the Company has not revised income statements or cash flows of any periods as the impact to all periods is minimal since the understated rebates liability was accumulated primarily prior to fiscal 2014. Based upon evaluation and consideration of provisions under ASC 250, Accounting Changes and Error Corrections, that incorporates SEC Staff Accounting Bulletin (SAB) No.99, Materiality , we determined that the impact is not material to our prior year's consolidated financial statements. However, we have revised our prior year Balance Sheet at October 31, 2016 in this Quarterly Report on Form 10-Q to reflect this adjustment. Accounting Pronouncements Issued Not Yet Adopted In March 2017, the FASB issued ASU 2017-07, Compensation - Retirement Benefits (Topic 715): Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost. The ASU requires an entity to disaggregate the service cost component from the other components of net benefit cost. The service cost component is presented in the same line items as other compensation costs arising from services rendered by the pertinent employees during the period and the other components of net benefit costs are presented separately as other income/expense below income from operations. We are currently evaluating the impact of ASU 2017-07, which is effective for the Company in our fiscal year and interim periods beginning November 1, 2018. In November 2016, the FASB issued ASU 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash. ASU 2016-18 provides guidance on the classification and presentation of changes in restricted cash and cash equivalents in the statement of cash flows. ASU 2016-18 will be effective for the Company in fiscal 2019 and is not expected to have a significant impact on the Company's Consolidated Statements of Cash Flows. Early adoption is permitted. In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). ASU 2016-01 requires that a lessee recognize the assets and liabilities that arise from operating leases. A lessee should recognize in the statement of financial position a liability to make lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying asset for the lease term. For leases with a term of 12 months or less, a lessee is permitted to make an accounting policy election by class of underlying asset not to recognize lease assets and lease liabilities. In transition, lessees and lessors are required to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach. We are currently evaluating the impact of ASU 2016-02, which is effective for the Company in our fiscal year and interim periods beginning on November 1, 2019. In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606) . ASU 2014-09 requires revenue recognition to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. ASU 2014-09 sets forth a new revenue recognition model that requires identifying the contract, identifying the performance obligations, determining the transaction price, allocating the transaction price to performance obligations and recognizing the revenue upon satisfaction of performance obligations. The amendments in the ASU can be applied either retrospectively to each prior reporting period presented or retrospectively with the cumulative effect of initially applying the update recognized at the date of the initial application along with additional disclosures. We are currently evaluating the impact of ASU 2014-09, which is effective for the Company in our fiscal year and interim periods beginning on November 1, 2018. Accounting Pronouncements Recently Adopted In January 2017, the FASB issued ASU 2017-04, Intangibles - Goodwill and other (Topic 350): Simplifying the Test for Goodwill Impairment. FASB eliminated Step 2 from the goodwill impairment test, which required a hypothetical purchase price allocation. Under the amendments in this update, an entity should perform goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount and recognize an impairment charge for the carrying amount which exceeds the reporting unit’s fair value. An entity still has the option to perform the qualitative assessment for a reporting unit to determine if the quantitative impairment test is necessary. The Company has elected to early adopt ASU 2017-04 effective in the third quarter of fiscal 2017. The adoption has no material impact on the Company's reported financial results. In January 2017, the FASB issued ASU 2017-01, Business Combination (Topic 805): Clarifying the Definition of a Business. ASU 2017-01 provides a new framework for determining whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The Company has elected to early adopt ASU 2017-01 effective in the second quarter of fiscal 2017. The adoption has no material impact for the Company. In March 2016, the FASB issued ASU 2016-09, Compensation- Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting , to improve the accounting for share-based payments to employees. ASU 2016-09 requires excess tax benefits (windfall tax benefits) and tax deficiencies (shortfalls) to be recognized as income tax expense or benefit in the income statement when awards vest or are settled. Companies will no longer record excess tax benefits and certain tax deficiencies in additional paid-in capital. This ASU also requires companies to classify cash flows resulting from employee share-based payments, including the additional tax benefits or expenses related to the vesting or settlement of share-based awards, as cash flows from operating activities rather than financing activities. The standard also allows for additional employee tax withholding on the exercise or release of awards, without triggering liability classification of the award. Finally, the update allows an accounting policy election for the treatment of forfeitures of stock based awards. Companies can elect to continue to estimate forfeitures expected to occur, or account for forfeitures as they occur. The Company has elected to early adopt ASU 2016-09 effective November 1, 2016. Accordingly, the Company recognized $17.9 million in deferred tax assets associated with excess tax benefits not previously recognized in deferred taxes as a cumulative-effect adjustment to retained earnings at November 1, 2016. The Company also recognized excess tax benefits as a discrete income tax benefit of $13.4 million during the first nine months of fiscal 2017, which is classified as an operating activity in the Consolidated Statements of Cash Flows on a prospective basis. The Company elected to continue to estimate forfeitures that are expected to occur when estimating the amount of compensation expense to record in each accounting period. In November 2015, the FASB issued ASU 2015-17, Balance Sheet Classification of Deferred Taxes, which requires entities to present all deferred tax assets and liabilities as noncurrent in the Balance Sheet. ASU 2015-17 can be early adopted for any period that has not been issued on a prospective or retrospective basis. The Company elected to early adopt this guidance on a prospective basis for the quarter ended January 31, 2017. No prior periods were retrospectively adjusted.

Acquisitions

Acquisitions	9 Months Ended
	Jul. 31, 2017
Business Combinations [Abstract]
Acquisitions	Acquisitions Fiscal Year 2017 On June 30, 2017 , we completed the acquisition of Grand Vista LLC, a long-standing distribution partner in Russia . The fair value of the consideration transferred for the acquisition was approximately $23.7 million in cash, $23.1 million net of cash acquired. Our preliminary allocation of the fair value of the purchase price includes $14.9 million for customer relationships; $10.3 million in goodwill; and $1.5 million in identifiable net liabilities. We are in the process of finalizing information related to assets, liabilities and the corresponding effect on goodwill. On November 4, 2016 , we completed the acquisition of Wallace, the in-vitro fertilization (IVF) segment of Smiths Medical International, Ltd., a division of Smiths Group plc. The fair value of the consideration transferred for the acquisition was approximately $167.4 million in cash. Our allocation of the fair value of the purchase price includes $72.2 million in identifiable intangible assets, consisting of $66.5 million for technology, $3.2 million for trade names and $2.5 million for customer relationships; $94.8 million in goodwill; and $0.4 million in identifiable net assets. Fiscal Year 2016 On May 31, 2016 we completed the acquisition of Reprogenetics UK, a UK based genetics laboratory specializing in service offerings of preimplantation genetic screening (PGS) and preimplantation genetic diagnosis (PGD) used during the IVF process. The fair value of the consideration transferred for the acquisition was approximately $11.7 million , $11.4 million net of cash acquired. Our allocation of the fair value of the purchase price includes $6.3 million in identifiable intangible assets, consisting of $5.1 million for customer relationships and $1.2 million for trade names; $5.6 million in goodwill; and $0.2 million in identifiable net liabilities. On May 25, 2016 , we completed the acquisition of Recombine Inc., a U.S. based clinical genetic testing company specializing in carrier screening. The fair value of the consideration transferred for the acquisition was approximately $84.4 million , $84.0 million net of cash acquired. Our allocation of the fair value of the purchase price includes $30.0 million in identifiable intangible assets, consisting of $23.1 million for technology, $2.4 million for customer relationships and $4.5 million for trade names; $65.0 million in goodwill; and $10.5 million in identifiable net liabilities. On May 4, 2016 , we completed the acquisition of Kivex Biotec A/S (K-Systems), a Danish manufacturer and distributor of equipment for IVF clinics. The fair value of the consideration transferred for the acquisition was approximately $11.7 million , $11.5 million net of cash acquired. Our allocation of the fair value of the purchase price includes $5.4 million in identifiable intangible assets, consisting of $3.6 million for Technology, $1.0 million for trade names and $0.8 million for customer relationships; $5.6 million in goodwill; and $0.7 million in identifiable net tangible assets. On March 31, 2016 we completed the acquisition of Genesis Genetics Inc., a U.S. based genetics laboratory specializing in preimplantation genetic screening and preimplantation genetic diagnosis used during the IVF process. The fair value of the consideration transferred for the acquisition was approximately $61.1 million in cash, $60.5 million net of cash acquired. Our allocation of the fair value of the purchase price includes $28.6 million in identifiable intangible assets, consisting of $25.2 million for customer relationships and $3.4 million for trade names; $28.7 million in goodwill; and $3.8 million in identifiable net tangible assets. On February 8, 2016 , we completed the acquisition of The Pipette Company, an Australian manufacturer and distributor of micro pipettes for the Assisted Reproductive Technology market. The fair value of the consideration transferred for the acquisition was approximately $20.2 million in cash, $19.6 million net of cash acquired. Our allocation of the fair value of the purchase price includes $5.6 million in identifiable intangible assets, consisting of $5.2 million for customer relationships and $0.4 million for trade names; $15.0 million in goodwill; and $0.4 million in identifiable net liabilities. On December 17, 2015 , we completed the acquisition of Research Instruments Limited, a UK manufacturer and supplier of IVF medical devices and systems. The fair value of the consideration transferred for the acquisition was approximately $53.6 million in cash, $50.0 million net of cash acquired. Our allocation of the fair value of the purchase price includes $10.3 million in identifiable intangible assets, consisting of $6.2 million for developed technology, $2.2 million of trade names and $1.9 million for customer relationships; $35.8 million in goodwill; and $7.6 million in identifiable net tangible assets. We believe these acquisitions strengthen CooperVision's business through the addition of new or complementary lens products and strengthen CooperSurgical's business through the addition of new or complementary products and services within IVF and our genetic testing platform. The pro forma results of operations of these acquisitions have not been presented because the effects of the business combinations described above, individually and in the aggregate, were not material to our consolidated results of operations.

Restructuring and Integration C

Restructuring and Integration Costs	9 Months Ended
	Jul. 31, 2017
Restructuring and Related Activities [Abstract]
Restructuring and Integration Costs	Restructuring and Integration Costs 2014 Sauflon Integration Plan During the fourth quarter of fiscal 2014 and in connection with the Sauflon acquisition, our CooperVision business unit initiated restructuring and integration activities to optimize operational synergies of the combined companies. These activities include product and equipment rationalization, workforce reductions and consolidation of duplicative facilities. At October 31, 2016 , our activities related to this restructuring and integration plan were essentially complete. The total restructuring costs under this plan were $148.3 million . There were no charges related to the 2014 Sauflon Integration Plan in the first nine months of fiscal 2017. In the three and nine month periods ended July 31, 2016, we recorded in cost of sales $8.7 million and $23.5 million of expense, respectively, arising from production-related asset disposals and accelerated depreciation on equipment, primarily related to our hydrogel lenses, based on our review of products, materials and manufacturing processes of Sauflon. We recorded in cost of sales, employee termination costs of $0.4 million and $0.9 million in the three and nine month periods ended July 31, 2016, respectively. We recorded $0.1 million of employee termination costs and $0.2 million for lease termination costs in selling, general and administrative expense in the nine months ended July 31, 2016. We also recorded in research and development expense $0.1 million of employee termination costs in the nine months ended July 31, 2016. In addition, CooperVision incurred $10.0 million of integration costs included in operating expenses in the nine months ended July 31, 2016, respectively. CooperVision did not incur integration costs in the first nine months of fiscal 2017. A summary of the cumulative total restructuring costs by major component recognized at October 31, 2016 , is as follows: (In millions) Employee-related Facilities-related Product Rationalization Total Cumulative amounts incurred as of October 31, 2016 $ 17.8 $ 1.1 $ 129.4 $ 148.3 The following table summarizes the restructuring activities by major component for the fiscal year ended October 31, 2016 and the nine months ended July 31, 2017 : (In millions) Employee-related Facilities-related Product Rationalization Total Balance at October 31, 2015 $ 8.6 $ 0.3 $ — $ 8.9 Additions during fiscal 2016 — 0.2 56.4 56.6 Payments during the fiscal year (5.2 ) (0.2 ) — (5.4 ) Non-cash adjustments (a) (b) (0.6 ) — (56.4 ) (57.0 ) Balance at October 31, 2016 $ 2.8 $ 0.3 $ — $ 3.1 Payments during the nine months ended July 31, 2017 (1.5 ) — — (1.5 ) Non-cash adjustments (a) (0.7 ) (0.3 ) — (1.0 ) Balance at July 31, 2017 $ 0.6 $ — $ — $ 0.6 (a) Represent adjustments for currency translation and accrual releases for employee and facilities-related. (b) Represents equipment disposals, inventory write-offs and accelerated depreciation for product rationalization.

Inventories

Inventories	9 Months Ended
	Jul. 31, 2017
Inventory Disclosure [Abstract]
Inventories	Inventories (In millions) July 31, 2017 October 31, 2016 Raw materials 104.7 86.0 Work-in-process 15.1 12.6 Finished goods 334.1 319.1 453.9 417.7 Inventories are stated at the lower of cost or net realizable value. Cost is computed using standard cost that approximates actual cost, on a first-in, first-out basis.

Intangible Assets

Intangible Assets	9 Months Ended
	Jul. 31, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	Intangible Assets Goodwill (In millions) CooperVision CooperSurgical Total Balance at October 31, 2015 $ 1,827.6 $ 369.5 $ 2,197.1 Net additions during the year ended October 31, 2016 9.1 156.9 166.0 Translation (190.3 ) (8.1 ) (198.4 ) Balance at October 31, 2016 1,646.4 518.3 2,164.7 Net additions during the nine months ended July 31, 2017 10.3 94.4 104.7 Translation 56.6 7.6 64.2 Balance at July 31, 2017 $ 1,713.3 $ 620.3 $ 2,333.6 We performed our annual impairment assessment in our third quarter of fiscal 2017 and 2016, and our analysis indicated that we had no impairment of goodwill. We evaluate goodwill for impairment annually during the fiscal third quarter and when an event occurs or circumstances change such that it is reasonably possible that impairment may exist. We account for goodwill and evaluate our goodwill balances and test them for impairment in accordance with related accounting standards. In the third quarter of fiscal 2017, we adopted ASU 2017-04, Intangibles - Goodwill and other (Topic 350): Simplifying the Test for Goodwill Impairment where FASB eliminated Step 2 from the goodwill impairment test, which required a hypothetical purchase price allocation. We performed a qualitative assessment to test each reporting unit's goodwill for impairment. Qualitative factors considered in this assessment include industry and market considerations, overall financial performance and other relevant events and factors affecting each reporting unit. Based on our qualitative assessment, if we determine that the fair value of a reporting unit is more likely than not to be less than its carrying amount, the fair value of a reporting unit will be compared with its carrying amount and an impairment charge will be recognized for the carrying amount which exceeds the reporting unit's fair value. A reporting unit is the level of reporting at which goodwill is tested for impairment. Our reporting units are the same as our business segments - CooperVision and CooperSurgical - reflecting the way that we manage our business. Goodwill impairment analysis and measurement is a process that requires significant judgment. If our common stock price trades below book value per share, there are changes in market conditions or future downturn in our business, or a future annual goodwill impairment test indicates an impairment of our goodwill, we may have to recognize a non-cash impairment of goodwill that could be material and could adversely affect our results of operations in the period recognized and also adversely affect our total assets, stockholders' equity and financial condition. Other Intangible Assets At July 31, 2017 At October 31, 2016 (In millions) Gross Carrying Amount Accumulated Amortization & Translation Gross Carrying Amount Accumulated Amortization & Translation Weighted Average Amortization Period (In years) Trademarks $ 40.7 $ 9.4 $ 36.6 $ 6.8 12 Technology 423.5 164.7 354.8 139.3 11 Customer relationships 310.3 139.3 285.7 121.9 13 License and distribution rights and other 68.9 42.1 65.8 33.8 9 843.4 $ 355.5 742.9 $ 301.8 12 Less: accumulated amortization and translation 355.5 301.8 Other intangible assets, net $ 487.9 $ 441.1 We estimate that amortization expense for our existing other intangible assets at July 31, 2017 , will be $67.7 million in fiscal 2017, $66.3 million in fiscal 2018, $63.9 million in fiscal 2019, $53.9 million in fiscal 2020 and $52.4 million in fiscal 2021.

Debt

Debt	9 Months Ended
	Jul. 31, 2017
Debt Disclosure [Abstract]
Debt	Debt (In millions) July 31, 2017 October 31, 2016 Short-term: Overdraft and other credit facilities $ 33.4 $ 17.1 Current portion of long-term debt — 210.7 Less unamortized debt issuance cost on term loans — (1.5 ) $ 33.4 $ 226.3 Long term: Credit Agreement $ 354.0 $ — Term loans 830.0 1,111.2 Other 0.2 0.2 Less unamortized debt issuance cost on term loans (4.2 ) (4.0 ) $ 1,180.0 $ 1,107.4 Revolving Credit and Term Loan Agreement on March 1, 2016 (2016 Credit Agreement) On March 1, 2016 , we entered into a new Revolving Credit and Term Loan Agreement (2016 Credit Agreement), among the Company, CooperVision International Holding Company, LP, the lenders party thereto and KeyBank National Association, as administrative agent. The 2016 Credit Agreement provides for a multicurrency revolving credit facility in an aggregate principal amount of $1.0 billion and a term loan facility in an aggregate principal amount of $830.0 million , each of which, unless terminated earlier, mature on March 1, 2021 . In addition, we have the ability from time to time to request an increase to the size of the revolving credit facility or establish one or more new term loans under the term loan facility in an aggregate amount up to $750.0 million , subject to the discretionary participation of the lenders. Amounts outstanding under the 2016 Credit Agreement will bear interest, at our option, at either the base rate, or the adjusted LIBO rate or adjusted foreign currency rate (each as defined in the 2016 Credit Agreement), plus, in each case, an applicable rate of between 0.00% and 0.75% in respect of base rate loans and between 1.00% and 1.75% in respect of adjusted LIBO rate or adjusted foreign currency rate loans, in each case in accordance with a pricing grid tied to the Total Leverage Ratio, as defined in the 2016 Credit Agreement. We pay an annual commitment fee that ranges from 0.125% to 0.25% of the unused portion of the revolving credit facility depending on certain financial ratios. In addition to the annual commitment fee described above, we are also required to pay certain letter of credit and related fronting fees and other administrative fees pursuant to the terms of the 2016 Credit Agreement. The 2016 Credit Agreement contains customary restrictive covenants, as well as financial covenants that require us to maintain a certain total leverage ratio and interest coverage ratio, each as defined in the 2016 Credit Agreement: • Interest Coverage Ratio, as defined, to be at least 3.00 to 1.00 at all times. • Total Leverage Ratio, as defined, to be no higher than 3.75 to 1.00 . At July 31, 2017 , we were in compliance with the Interest Coverage Ratio at 24.08 and the Total Leverage Ratio at 1.70 . At July 31, 2017 , we had $830.0 million outstanding under the Term Loan and $645.7 million available under the Revolving Credit Agreement. Refer to our Annual Report on Form 10-K for the fiscal year ended October 31, 2016 for more details. $700.0 million Term Loan and $300 million Term Loan On August 4, 2014 , we entered into a three -year, $700.0 million , senior unsecured term loan agreement by and among the Company, the lenders party thereto and KeyBank National Association as administrative agent (as subsequently amended, the 2014 Term Loan Agreement) with a maturity date of August 4, 2017 . In August 2014, we utilized this facility to fund the acquisition of Sauflon, as well as to provide working capital and for general corporate purposes. We repaid $493.0 million of the outstanding balance in fiscal 2016 and fully repaid the remaining outstanding balance of $207.0 million in the second quarter of fiscal 2017 using the funds from the 2016 Credit Agreement, as well as from cash provided by operations. At July 31, 2017 , we had no outstanding balance under the 2014 Term Loan. On September 12, 2013 , the Company entered into a five -year, $300.0 million , senior unsecured term loan agreement by and among the Company; the lenders party thereto and KeyBank National Association, as administrative agent (as subsequently amended, the 2013 Term Loan Agreement), with a maturity date of September 12, 2018 , subject to amortization of principal of 5% per annum payable quarterly beginning October 31, 2016 , with the balance payable at maturity. In fiscal 2016, we repaid $15.0 million of the outstanding balance and fully repaid the remaining outstanding balance of $285.0 million in May 2017 using the funds from the 2016 Credit Agreement. At July 31, 2017 , we had no outstanding balance under the 2013 Term Loan. Amounts outstanding under the 2014 and 2013 Term Loan Agreements (Term Loan Agreements) bear interest, at our option, at either the base rate, or the adjusted LIBO rate (each as defined in the Term Loan Agreements), plus, in each case, an applicable rate of between 0.00% and 0.50% in respect of base rate loans and between 0.75% and 1.50% in respect of adjusted LIBO rate loans, in each case in accordance with a pricing grid tied to the Total Leverage Ratio, as defined in the Term Loan Agreements. These Term Loan Agreements contain customary restrictive covenants, as well as financial covenants that require the Company to maintain a certain Total Leverage Ratio and Interest Coverage Ratio, each as defined in the agreements, consistent with the 2016 Credit Agreement discussed above. Refer to our Annual Report on Form 10-K for the fiscal year ended October 31, 2016 for more details.

Income Taxes

Income Taxes	9 Months Ended
	Jul. 31, 2017
Components of Income Tax Expense (Benefit), Continuing Operations [Abstract]
Income Taxes	Income Taxes Our effective tax rate (ETR) (provision for income taxes divided by pretax income) for the first nine months of fiscal 2017 was 4.4% . Our year-to-date results reflect the projected fiscal year ETR, plus any discrete items. The ETR used to record the provision for income taxes for the first nine months of fiscal 2016 was 5.4% . The decrease in the effective tax rate in the first nine months of fiscal 2017 reflects a shift in our geographic mix of income as well as the benefit from adopting ASU 2016-09 (Excess tax benefit from share-based compensation). We recognize the benefit from a tax position only if it is more likely than not that the position would be sustained upon audit based solely on the technical merits of the tax position. At November 1, 2016, Cooper had unrecognized tax benefits of $39.9 million , of which, if recognized, $29.7 million would impact our ETR. For the first nine months of fiscal 2017, there were no material changes to the total amount of unrecognized tax benefits. We have accrued $3.7 million of interest and penalties as of November 1, 2016. It is our policy to recognize the items of interest and penalties directly related to income taxes as additional income tax expense. Included in the balance of unrecognized tax benefits at November 1, 2016, is $1.6 million related to tax positions for which it is reasonably possible that the total amounts could significantly change during the next twelve months. This amount represents a decrease in unrecognized tax benefits related to expiring statutes in various jurisdictions worldwide and relates primarily to transfer pricing matters. At July 31, 2017 , the tax years for which Cooper remains subject to United States Federal income tax assessment upon examination are 2014 through 2016. Cooper remains subject to income tax examinations in other significant tax jurisdictions including the United Kingdom, Japan, France and Australia for the tax years 2013 through 2016.

Earnings Per Share

Earnings Per Share	9 Months Ended
	Jul. 31, 2017
Earnings Per Share [Abstract]
Earnings Per Share	Earnings Per Share Periods Ended July 31, Three Months Nine Months (In millions, except per share amounts) 2017 2016 2017 2016 Net income attributable to Cooper stockholders $ 103.6 $ 87.9 $ 284.3 $ 213.4 Basic: Weighted average common shares 48.9 48.6 48.9 48.4 Basic earnings per common share attributable to Cooper stockholders $ 2.12 $ 1.81 $ 5.81 $ 4.41 Diluted: Weighted average common shares 48.9 48.6 48.9 48.4 Effect of potential dilutive common shares 0.7 0.4 0.6 0.5 Diluted weighted average common shares 49.6 49.0 49.5 48.9 Diluted earnings per common share attributable to Cooper stockholders $ 2.09 $ 1.79 $ 5.74 $ 4.36 The following table sets forth stock options to purchase Cooper’s common stock and restricted stock units that were not included in the diluted earnings per share calculation because their effect would have been antidilutive for the periods presented: Periods Ended July 31, Three Months Nine Months (In thousands, except exercise prices) 2017 2016 2017 2016 Number of stock option shares excluded — 49 192 418 Range of exercise prices $ — $ 162.28 $ 175.31 $131.60-$162.69 Numbers of restricted stock units excluded 2 1 3 3

Share-Based Compensation Plans

Share-Based Compensation Plans	9 Months Ended
	Jul. 31, 2017
Share-based Compensation [Abstract]
Share-Based Compensation Plans	Share-Based Compensation Plans Cooper has several share-based compensation plans that are described in the Company’s Annual Report on Form 10‑K for the fiscal year ended October 31, 2016 . The compensation expense and related income tax benefit recognized in our consolidated condensed financial statements for share-based awards were as follows: Periods Ended July 31, Three Months Nine Months (In millions) 2017 2016 2017 2016 Selling, general and administrative expense $ 7.7 $ 6.4 $ 24.9 $ 19.2 Cost of sales (0.1 ) 0.7 1.9 1.8 Research and development expense 0.3 0.3 0.9 0.9 Total share-based compensation expense $ 7.9 $ 7.4 $ 27.7 $ 21.9 Related income tax benefit $ 2.6 $ 2.2 $ 8.5 $ 6.5 We capitalized share-based compensation expense as part of the cost of inventory in the amounts of $0.8 million and $2.8 million during the three and nine months ended July 31, 2017 , respectively; and $0.7 million and $1.8 million during the three and nine months ended July 31, 2016 , respectively. In the third quarter of fiscal 2017, there was an adjustment to cost of sales of $0.9 million to increase share-based compensation capitalized in inventory.

Stockholders' Equity

Stockholders' Equity	9 Months Ended
	Jul. 31, 2017
Equity [Abstract]
Stockholders' Equity	Stockholders’ Equity Analysis of Changes in Accumulated Other Comprehensive Income (Loss): (In millions) Foreign Currency Translation Adjustment Minimum Pension Liability Total Balance at October 31, 2015 $ (171.8 ) $ (19.8 ) $ (191.6 ) Gross change in value during the year ended October 31, 2016 (289.6 ) (13.7 ) (303.3 ) Tax effect for the period — 5.3 5.3 Balance at October 31, 2016 $ (461.4 ) $ (28.2 ) $ (489.6 ) Gross change in value during the nine months ended July 31, 2017 104.8 — 104.8 Balance at July 31, 2017 $ (356.6 ) $ (28.2 ) $ (384.8 ) Share Repurchases In December 2011, our Board of Directors authorized the 2012 Share Repurchase Program and through subsequent amendments, the most recent in March 2017, the total repurchase authorization was increased from $500.0 million to $1.0 billion of the Company’s common stock. This program has no expiration date and may be discontinued at any time. Purchases under the 2012 Share Repurchase Program are subject to a review of the circumstances in place at the time and may be made from time to time as permitted by securities laws and other legal requirements. We did not repurchase shares in the third quarter of fiscal 2017. During the second quarter of fiscal 2017, we repurchased 150 thousand shares of our common stock for $29.5 million at an average price of $196.82 . At July 31, 2017 , $589.0 million remains authorized for repurchase under the program. We did not repurchase shares during the first nine months of fiscal 2016. Dividends We paid a semiannual dividend of approximately $1.5 million or 3 cents per share on February 9, 2017, to stockholders of record on January 23, 2017 . We paid another semiannual dividend of approximately $1.5 million or 3 cents per share on August 7, 2017 , to stockholders of record on July 21, 2017 .

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Jul. 31, 2017
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements At July 31, 2017 and October 31, 2016 , the carrying value of cash and cash equivalents, accounts receivable, prepaid expense and other current assets, lines of credit, accounts payable and other current liabilities approximate fair value due to the short-term nature of such instruments and the ability to obtain financing on similar terms. Assets and liabilities are measured and reported at fair value per related accounting standards that define fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value hierarchy prioritizes the inputs to valuation techniques used to measure fair value. An asset’s or liability’s level is based on the lowest level of input that is significant to the fair value measurement. Assets and liabilities carried at fair value are valued and disclosed in one of the following three levels of the valuation hierarchy: Level 1: Quoted market prices in active markets for identical assets or liabilities. Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data. Level 3: Unobservable inputs reflecting the reporting entity’s own assumptions. We believe that the balances of our revolving credit agreement and term loans approximated their fair values at July 31, 2017 and October 31, 2016 and are categorized as Level 2 of the fair value hierarchy.

Employee Benefits

Employee Benefits	9 Months Ended
	Jul. 31, 2017
General Discussion of Pension and Other Postretirement Benefits [Abstract]
Employee Benefits	Employee Benefits Cooper’s Retirement Income Plan (Plan), a defined benefit plan, covers substantially all full-time United States employees. Our contributions are designed to fund normal cost on a current basis and to fund the estimated prior service cost of benefit improvements. The unit credit actuarial cost method is used to determine the annual cost. Cooper pays the entire cost of the Plan and funds such costs as they accrue. Virtually all of the assets of the Plan are comprised of equities and participation in equity and fixed income funds. Our results of operations for the three and nine months ended July 31, 2017 and 2016 reflect the following components of net periodic pension costs: Periods Ended July 31, Three Months Nine Months (In millions) 2017 2016 2017 2016 Service cost $ 2.5 $ 2.3 $ 7.5 $ 6.9 Interest cost 1.1 1.2 3.3 3.7 Expected return on plan assets (1.8 ) (1.6 ) (5.4 ) (4.9 ) Recognized net actuarial loss 0.7 0.4 2.1 1.2 Net periodic pension cost $ 2.5 $ 2.3 $ 7.5 $ 6.9 We contributed $5.0 million to the Plan in the first nine months of fiscal 2017, and expect to contribute an additional $5.0 million during the remainder of fiscal 2017. We contributed $5.0 million to the Plan in the first nine months of fiscal 2016. The expected rate of return on plan assets for determining net periodic pension cost is 8% .

Contingencies

Contingencies	9 Months Ended
	Jul. 31, 2017
Commitments and Contingencies Disclosure [Abstract]
Contingencies	Contingencies Since March 2015, over 50 putative class action complaints were filed by contact lens consumers alleging that contact lens manufacturers, in conjunction with their respective Unilateral Pricing Policy (UPP), conspired to reach agreements between each other and certain distributors and retailers regarding the prices at which certain contact lenses could be sold to consumers. The plaintiffs are seeking damages against CooperVision, Inc., other contact lens manufacturers, distributors and retailers, in various courts around the United States. In June 2015, all of the class action cases were consolidated and transferred to the United States District Court for the Middle District of Florida. CooperVision and the other defendants jointly filed a motion to dismiss the complaints in December 2015. In June 2016, the motion to dismiss with respect to claims brought under the Maryland Consumer Protection Act was granted, but the motion to dismiss with respect to claims brought under Section 1 of the Sherman Act and other state laws was denied. The actions currently are in discovery. In March 2017, the plaintiffs filed a motion for class certification. In August 2017, CooperVision entered into a settlement agreement with the plaintiffs, without any admission of liability, to settle all claims against CooperVision, subject to Court approval of the settlement. The Company has recorded a settlement accrual of $3.0 million for the third quarter fiscal ended July 31, 2017. The Company is involved in various lawsuits, claims and other legal matters from time to time that arise in the ordinary course of conducting business, including matters involving our products, intellectual property, supplier relationships, distributors, competitor relationships, employees and other matters. Legal fees are recognized as incurred.

Business Segment Information

Business Segment Information	9 Months Ended
	Jul. 31, 2017
Segment Reporting [Abstract]
Business Segment Information	Business Segment Information Cooper uses operating income, as presented in our financial reports, as the primary measure of segment profitability. We do not allocate costs from corporate functions to segment operating income. Items below operating income are not considered when measuring the profitability of a segment. We use the same accounting policies to generate segment results as we do for our consolidated results. Total assets are those used in continuing operations except cash and cash equivalents, which we include as corporate assets. Segment information: Periods Ended July 31, Three Months Nine Months (In millions) 2017 2016 2017 2016 CooperVision net sales by category: Toric lens $ 138.3 $ 126.1 $ 390.8 $ 354.1 Multifocal lens 46.8 44.3 132.1 127.2 Single-use sphere lens 115.8 104.3 319.5 292.7 Non single-use sphere and other 136.4 135.2 392.6 391.5 Total CooperVision net sales 437.3 409.9 1,235.0 1,165.5 CooperSurgical net sales 118.7 104.8 342.5 282.7 Total net sales $ 556.0 $ 514.7 $ 1,577.5 $ 1,448.2 Operating income (loss): CooperVision $ 109.5 $ 99.4 $ 308.9 $ 235.7 CooperSurgical 14.9 14.7 48.2 47.9 Corporate (11.6 ) (11.4 ) (36.5 ) (33.7 ) Total operating income 112.8 102.7 320.6 249.9 Interest expense 8.3 8.0 23.3 20.9 Other (income) expense, net (3.2 ) 1.3 (0.1 ) 2.2 Income before income taxes $ 107.7 $ 93.4 $ 297.4 $ 226.8 (In millions) July 31, 2017 October 31, 2016 Total assets: CooperVision $ 3,515.8 $ 3,382.4 CooperSurgical 1,116.2 907.1 Corporate 150.8 189.1 Total $ 4,782.8 $ 4,478.6 Geographic information: Periods Ended July 31, Three Months Nine Months (In millions) 2017 2016 2017 2016 Net sales to external customers by country of domicile: United States $ 235.3 $ 227.8 $ 694.8 $ 656.0 Europe 200.6 182.8 544.5 505.8 Rest of world 120.1 104.1 338.2 286.4 Total $ 556.0 $ 514.7 $ 1,577.5 $ 1,448.2 (In millions) July 31, 2017 October 31, 2016 Net property, plant and equipment by country of domicile: United States $ 467.7 $ 464.1 Europe 345.4 334.4 Rest of world 81.8 79.2 Total $ 894.9 $ 877.7

General (Policies)

General (Policies)	9 Months Ended
	Jul. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accounting Changes and Error Corrections	During the first quarter of fiscal 2017, the Company identified and recorded an amount of $4.1 million , net of income tax expense, to reflect a net cumulative decrease to retained earnings as of the opening balance sheet for the fiscal year ended October 31, 2016 and a corresponding net increase in other current liabilities and deferred tax asset, all associated with an understatement of accruals for rebates in prior years. Accordingly, the Company has not revised income statements or cash flows of any periods as the impact to all periods is minimal since the understated rebates liability was accumulated primarily prior to fiscal 2014. Based upon evaluation and consideration of provisions under ASC 250, Accounting Changes and Error Corrections, that incorporates SEC Staff Accounting Bulletin (SAB) No.99, Materiality , we determined that the impact is not material to our prior year's consolidated financial statements. However, we have revised our prior year Balance Sheet at October 31, 2016 in this Quarterly Report on Form 10-Q to reflect this adjustment.
Accounting Pronouncements Issued Not Yet Adopted and Accounting Pronouncements Recently Adopted	Accounting Pronouncements Issued Not Yet Adopted In March 2017, the FASB issued ASU 2017-07, Compensation - Retirement Benefits (Topic 715): Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost. The ASU requires an entity to disaggregate the service cost component from the other components of net benefit cost. The service cost component is presented in the same line items as other compensation costs arising from services rendered by the pertinent employees during the period and the other components of net benefit costs are presented separately as other income/expense below income from operations. We are currently evaluating the impact of ASU 2017-07, which is effective for the Company in our fiscal year and interim periods beginning November 1, 2018. In November 2016, the FASB issued ASU 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash. ASU 2016-18 provides guidance on the classification and presentation of changes in restricted cash and cash equivalents in the statement of cash flows. ASU 2016-18 will be effective for the Company in fiscal 2019 and is not expected to have a significant impact on the Company's Consolidated Statements of Cash Flows. Early adoption is permitted. In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). ASU 2016-01 requires that a lessee recognize the assets and liabilities that arise from operating leases. A lessee should recognize in the statement of financial position a liability to make lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying asset for the lease term. For leases with a term of 12 months or less, a lessee is permitted to make an accounting policy election by class of underlying asset not to recognize lease assets and lease liabilities. In transition, lessees and lessors are required to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach. We are currently evaluating the impact of ASU 2016-02, which is effective for the Company in our fiscal year and interim periods beginning on November 1, 2019. In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606) . ASU 2014-09 requires revenue recognition to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. ASU 2014-09 sets forth a new revenue recognition model that requires identifying the contract, identifying the performance obligations, determining the transaction price, allocating the transaction price to performance obligations and recognizing the revenue upon satisfaction of performance obligations. The amendments in the ASU can be applied either retrospectively to each prior reporting period presented or retrospectively with the cumulative effect of initially applying the update recognized at the date of the initial application along with additional disclosures. We are currently evaluating the impact of ASU 2014-09, which is effective for the Company in our fiscal year and interim periods beginning on November 1, 2018. Accounting Pronouncements Recently Adopted In January 2017, the FASB issued ASU 2017-04, Intangibles - Goodwill and other (Topic 350): Simplifying the Test for Goodwill Impairment. FASB eliminated Step 2 from the goodwill impairment test, which required a hypothetical purchase price allocation. Under the amendments in this update, an entity should perform goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount and recognize an impairment charge for the carrying amount which exceeds the reporting unit’s fair value. An entity still has the option to perform the qualitative assessment for a reporting unit to determine if the quantitative impairment test is necessary. The Company has elected to early adopt ASU 2017-04 effective in the third quarter of fiscal 2017. The adoption has no material impact on the Company's reported financial results. In January 2017, the FASB issued ASU 2017-01, Business Combination (Topic 805): Clarifying the Definition of a Business. ASU 2017-01 provides a new framework for determining whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The Company has elected to early adopt ASU 2017-01 effective in the second quarter of fiscal 2017. The adoption has no material impact for the Company. In March 2016, the FASB issued ASU 2016-09, Compensation- Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting , to improve the accounting for share-based payments to employees. ASU 2016-09 requires excess tax benefits (windfall tax benefits) and tax deficiencies (shortfalls) to be recognized as income tax expense or benefit in the income statement when awards vest or are settled. Companies will no longer record excess tax benefits and certain tax deficiencies in additional paid-in capital. This ASU also requires companies to classify cash flows resulting from employee share-based payments, including the additional tax benefits or expenses related to the vesting or settlement of share-based awards, as cash flows from operating activities rather than financing activities. The standard also allows for additional employee tax withholding on the exercise or release of awards, without triggering liability classification of the award. Finally, the update allows an accounting policy election for the treatment of forfeitures of stock based awards. Companies can elect to continue to estimate forfeitures expected to occur, or account for forfeitures as they occur. The Company has elected to early adopt ASU 2016-09 effective November 1, 2016. Accordingly, the Company recognized $17.9 million in deferred tax assets associated with excess tax benefits not previously recognized in deferred taxes as a cumulative-effect adjustment to retained earnings at November 1, 2016. The Company also recognized excess tax benefits as a discrete income tax benefit of $13.4 million during the first nine months of fiscal 2017, which is classified as an operating activity in the Consolidated Statements of Cash Flows on a prospective basis. The Company elected to continue to estimate forfeitures that are expected to occur when estimating the amount of compensation expense to record in each accounting period. In November 2015, the FASB issued ASU 2015-17, Balance Sheet Classification of Deferred Taxes, which requires entities to present all deferred tax assets and liabilities as noncurrent in the Balance Sheet. ASU 2015-17 can be early adopted for any period that has not been issued on a prospective or retrospective basis. The Company elected to early adopt this guidance on a prospective basis for the quarter ended January 31, 2017. No prior periods were retrospectively adjusted.

Restructuring and Integration22

Restructuring and Integration Costs (Tables)	9 Months Ended
	Jul. 31, 2017
Restructuring and Related Activities [Abstract]
Schedule of Restructuring Costs	A summary of the cumulative total restructuring costs by major component recognized at October 31, 2016 , is as follows: (In millions) Employee-related Facilities-related Product Rationalization Total Cumulative amounts incurred as of October 31, 2016 $ 17.8 $ 1.1 $ 129.4 $ 148.3 The following table summarizes the restructuring activities by major component for the fiscal year ended October 31, 2016 and the nine months ended July 31, 2017 : (In millions) Employee-related Facilities-related Product Rationalization Total Balance at October 31, 2015 $ 8.6 $ 0.3 $ — $ 8.9 Additions during fiscal 2016 — 0.2 56.4 56.6 Payments during the fiscal year (5.2 ) (0.2 ) — (5.4 ) Non-cash adjustments (a) (b) (0.6 ) — (56.4 ) (57.0 ) Balance at October 31, 2016 $ 2.8 $ 0.3 $ — $ 3.1 Payments during the nine months ended July 31, 2017 (1.5 ) — — (1.5 ) Non-cash adjustments (a) (0.7 ) (0.3 ) — (1.0 ) Balance at July 31, 2017 $ 0.6 $ — $ — $ 0.6 (a) Represent adjustments for currency translation and accrual releases for employee and facilities-related. (b) Represents equipment disposals, inventory write-offs and accelerated depreciation for product rationalization.

Inventories (Tables)

Inventories (Tables)	9 Months Ended
	Jul. 31, 2017
Inventory Disclosure [Abstract]
Schedule of Inventories	(In millions) July 31, 2017 October 31, 2016 Raw materials 104.7 86.0 Work-in-process 15.1 12.6 Finished goods 334.1 319.1 453.9 417.7

Intangible Assets (Tables)

Intangible Assets (Tables)	9 Months Ended
	Jul. 31, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Goodwill	Goodwill (In millions) CooperVision CooperSurgical Total Balance at October 31, 2015 $ 1,827.6 $ 369.5 $ 2,197.1 Net additions during the year ended October 31, 2016 9.1 156.9 166.0 Translation (190.3 ) (8.1 ) (198.4 ) Balance at October 31, 2016 1,646.4 518.3 2,164.7 Net additions during the nine months ended July 31, 2017 10.3 94.4 104.7 Translation 56.6 7.6 64.2 Balance at July 31, 2017 $ 1,713.3 $ 620.3 $ 2,333.6
Schedule of Other Intangible Assets	Other Intangible Assets At July 31, 2017 At October 31, 2016 (In millions) Gross Carrying Amount Accumulated Amortization & Translation Gross Carrying Amount Accumulated Amortization & Translation Weighted Average Amortization Period (In years) Trademarks $ 40.7 $ 9.4 $ 36.6 $ 6.8 12 Technology 423.5 164.7 354.8 139.3 11 Customer relationships 310.3 139.3 285.7 121.9 13 License and distribution rights and other 68.9 42.1 65.8 33.8 9 843.4 $ 355.5 742.9 $ 301.8 12 Less: accumulated amortization and translation 355.5 301.8 Other intangible assets, net $ 487.9 $ 441.1

Debt (Tables)

Debt (Tables)	9 Months Ended
	Jul. 31, 2017
Debt Disclosure [Abstract]
Schedule of Debt	(In millions) July 31, 2017 October 31, 2016 Short-term: Overdraft and other credit facilities $ 33.4 $ 17.1 Current portion of long-term debt — 210.7 Less unamortized debt issuance cost on term loans — (1.5 ) $ 33.4 $ 226.3 Long term: Credit Agreement $ 354.0 $ — Term loans 830.0 1,111.2 Other 0.2 0.2 Less unamortized debt issuance cost on term loans (4.2 ) (4.0 ) $ 1,180.0 $ 1,107.4

Earnings Per Share (Tables)

Earnings Per Share (Tables)	9 Months Ended
	Jul. 31, 2017
Earnings Per Share [Abstract]
Schedule of Earnings Per Share	Periods Ended July 31, Three Months Nine Months (In millions, except per share amounts) 2017 2016 2017 2016 Net income attributable to Cooper stockholders $ 103.6 $ 87.9 $ 284.3 $ 213.4 Basic: Weighted average common shares 48.9 48.6 48.9 48.4 Basic earnings per common share attributable to Cooper stockholders $ 2.12 $ 1.81 $ 5.81 $ 4.41 Diluted: Weighted average common shares 48.9 48.6 48.9 48.4 Effect of potential dilutive common shares 0.7 0.4 0.6 0.5 Diluted weighted average common shares 49.6 49.0 49.5 48.9 Diluted earnings per common share attributable to Cooper stockholders $ 2.09 $ 1.79 $ 5.74 $ 4.36
Schedule of Stock Options to Purchase Common Stock Not Included in Diluted Net Income Per Share Calculation	The following table sets forth stock options to purchase Cooper’s common stock and restricted stock units that were not included in the diluted earnings per share calculation because their effect would have been antidilutive for the periods presented: Periods Ended July 31, Three Months Nine Months (In thousands, except exercise prices) 2017 2016 2017 2016 Number of stock option shares excluded — 49 192 418 Range of exercise prices $ — $ 162.28 $ 175.31 $131.60-$162.69 Numbers of restricted stock units excluded 2 1 3 3

Share-Based Compensation Plans

Share-Based Compensation Plans (Tables)	9 Months Ended
	Jul. 31, 2017
Share-based Compensation [Abstract]
Schedule of Compensation Expense and Related Income Tax Benefit for Share-Based Awards	The compensation expense and related income tax benefit recognized in our consolidated condensed financial statements for share-based awards were as follows: Periods Ended July 31, Three Months Nine Months (In millions) 2017 2016 2017 2016 Selling, general and administrative expense $ 7.7 $ 6.4 $ 24.9 $ 19.2 Cost of sales (0.1 ) 0.7 1.9 1.8 Research and development expense 0.3 0.3 0.9 0.9 Total share-based compensation expense $ 7.9 $ 7.4 $ 27.7 $ 21.9 Related income tax benefit $ 2.6 $ 2.2 $ 8.5 $ 6.5

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	9 Months Ended
	Jul. 31, 2017
Equity [Abstract]
Schedule of Accumulated Other Comprehensive Income (Loss)	Analysis of Changes in Accumulated Other Comprehensive Income (Loss): (In millions) Foreign Currency Translation Adjustment Minimum Pension Liability Total Balance at October 31, 2015 $ (171.8 ) $ (19.8 ) $ (191.6 ) Gross change in value during the year ended October 31, 2016 (289.6 ) (13.7 ) (303.3 ) Tax effect for the period — 5.3 5.3 Balance at October 31, 2016 $ (461.4 ) $ (28.2 ) $ (489.6 ) Gross change in value during the nine months ended July 31, 2017 104.8 — 104.8 Balance at July 31, 2017 $ (356.6 ) $ (28.2 ) $ (384.8 )

Employee Benefits (Tables)

Employee Benefits (Tables)	9 Months Ended
	Jul. 31, 2017
General Discussion of Pension and Other Postretirement Benefits [Abstract]
Schedule of Components of Net Periodic Pension Costs	Our results of operations for the three and nine months ended July 31, 2017 and 2016 reflect the following components of net periodic pension costs: Periods Ended July 31, Three Months Nine Months (In millions) 2017 2016 2017 2016 Service cost $ 2.5 $ 2.3 $ 7.5 $ 6.9 Interest cost 1.1 1.2 3.3 3.7 Expected return on plan assets (1.8 ) (1.6 ) (5.4 ) (4.9 ) Recognized net actuarial loss 0.7 0.4 2.1 1.2 Net periodic pension cost $ 2.5 $ 2.3 $ 7.5 $ 6.9

Business Segment Information (T

Business Segment Information (Tables)	9 Months Ended
	Jul. 31, 2017
Segment Reporting [Abstract]
Schedule of Segment Information	Segment information: Periods Ended July 31, Three Months Nine Months (In millions) 2017 2016 2017 2016 CooperVision net sales by category: Toric lens $ 138.3 $ 126.1 $ 390.8 $ 354.1 Multifocal lens 46.8 44.3 132.1 127.2 Single-use sphere lens 115.8 104.3 319.5 292.7 Non single-use sphere and other 136.4 135.2 392.6 391.5 Total CooperVision net sales 437.3 409.9 1,235.0 1,165.5 CooperSurgical net sales 118.7 104.8 342.5 282.7 Total net sales $ 556.0 $ 514.7 $ 1,577.5 $ 1,448.2 Operating income (loss): CooperVision $ 109.5 $ 99.4 $ 308.9 $ 235.7 CooperSurgical 14.9 14.7 48.2 47.9 Corporate (11.6 ) (11.4 ) (36.5 ) (33.7 ) Total operating income 112.8 102.7 320.6 249.9 Interest expense 8.3 8.0 23.3 20.9 Other (income) expense, net (3.2 ) 1.3 (0.1 ) 2.2 Income before income taxes $ 107.7 $ 93.4 $ 297.4 $ 226.8
Schedule of Identifiable Assets by Segment	(In millions) July 31, 2017 October 31, 2016 Total assets: CooperVision $ 3,515.8 $ 3,382.4 CooperSurgical 1,116.2 907.1 Corporate 150.8 189.1 Total $ 4,782.8 $ 4,478.6
Schedule of Net Sales to External Customers by Country of Domicile	Geographic information: Periods Ended July 31, Three Months Nine Months (In millions) 2017 2016 2017 2016 Net sales to external customers by country of domicile: United States $ 235.3 $ 227.8 $ 694.8 $ 656.0 Europe 200.6 182.8 544.5 505.8 Rest of world 120.1 104.1 338.2 286.4 Total $ 556.0 $ 514.7 $ 1,577.5 $ 1,448.2
Schedule of Long-Lived Assets by Country of Domicile	(In millions) July 31, 2017 October 31, 2016 Net property, plant and equipment by country of domicile: United States $ 467.7 $ 464.1 Europe 345.4 334.4 Rest of world 81.8 79.2 Total $ 894.9 $ 877.7

General Accounting Pronouncemen

General Accounting Pronouncements (Details) - USD ($) $ in Millions	3 Months Ended	9 Months Ended
	Jan. 31, 2017	Jul. 31, 2017	Nov. 01, 2016
Accounting Standards Update 2016-09 [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Excess tax benefit, amount		$ 13.4
Retained Earnings [Member] | Accounting Standards Update 2016-09 [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cumulative effect adjustment			$ 17.9
Rebate Accruals [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cumulative Effect on Retained Earnings, Net of Tax	$ (4.1)
Cumulative effect on retained earnings, net of tax	$ (4.1)

Acquisitions (Details)

Acquisitions (Details) - USD ($) $ in Millions	Jun. 30, 2017	Nov. 04, 2016	May 31, 2016	May 25, 2016	May 04, 2016	Mar. 31, 2016	Feb. 08, 2016	Dec. 17, 2015
Grand Vista [Member]
Business Acquisition [Line Items]
Business acquisition, effective date of acquisition	Jun. 30, 2017
Total purchase consideration	$ 23.7
Goodwill, acquired during period	10.3
Recognized identifiable assets (liabilities)	(1.5)
Payments to acquire businesses, net of cash acquired	23.1
Wallace [Member]
Business Acquisition [Line Items]
Business acquisition, effective date of acquisition		Nov. 4, 2016
Total purchase consideration		$ 167.4
Identifiable intangible assets		72.2
Goodwill, acquired during period		94.8
Recognized identifiable assets (liabilities)		0.4
Reprogenetics UK [Member]
Business Acquisition [Line Items]
Business acquisition, effective date of acquisition			May 31, 2016
Total purchase consideration			$ 11.7
Identifiable intangible assets			6.3
Goodwill, acquired during period			5.6
Recognized identifiable assets (liabilities)			(0.2)
Payments to acquire businesses, net of cash acquired			11.4
Recombine [Member]
Business Acquisition [Line Items]
Business acquisition, effective date of acquisition				May 25, 2016
Total purchase consideration				$ 84.4
Identifiable intangible assets				30
Goodwill, acquired during period				65
Recognized identifiable assets (liabilities)				(10.5)
Payments to acquire businesses, net of cash acquired				84
K-Systems [Member]
Business Acquisition [Line Items]
Business acquisition, effective date of acquisition					May 4, 2016
Total purchase consideration					$ 11.7
Identifiable intangible assets					5.4
Goodwill, acquired during period					5.6
Recognized identifiable assets (liabilities)					0.7
Payments to acquire businesses, net of cash acquired					11.5
Genesis Genetics [Member]
Business Acquisition [Line Items]
Business acquisition, effective date of acquisition						Mar. 31, 2016
Total purchase consideration						$ 61.1
Identifiable intangible assets						28.6
Goodwill, acquired during period						28.7
Recognized identifiable assets (liabilities)						3.8
Payments to acquire businesses, net of cash acquired						60.5
The Pipette Company [Member]
Business Acquisition [Line Items]
Business acquisition, effective date of acquisition							Feb. 8, 2016
Total purchase consideration							$ 20.2
Identifiable intangible assets							5.6
Goodwill, acquired during period							15
Recognized identifiable assets (liabilities)							(0.4)
Payments to acquire businesses, net of cash acquired							19.6
Research Instruments [Member]
Business Acquisition [Line Items]
Business acquisition, effective date of acquisition								Dec. 17, 2015
Total purchase consideration								$ 53.6
Identifiable intangible assets								10.3
Goodwill, acquired during period								35.8
Recognized identifiable assets (liabilities)								7.6
Payments to acquire businesses, net of cash acquired								50
Technology | Wallace [Member]
Business Acquisition [Line Items]
Identifiable intangible assets		66.5
Technology | Recombine [Member]
Business Acquisition [Line Items]
Identifiable intangible assets				23.1
Technology | K-Systems [Member]
Business Acquisition [Line Items]
Identifiable intangible assets					3.6
Technology | Research Instruments [Member]
Business Acquisition [Line Items]
Identifiable intangible assets								6.2
Trade Names [Member] | Wallace [Member]
Business Acquisition [Line Items]
Identifiable intangible assets		3.2
Trade Names [Member] | Reprogenetics UK [Member]
Business Acquisition [Line Items]
Identifiable intangible assets			1.2
Trade Names [Member] | Recombine [Member]
Business Acquisition [Line Items]
Identifiable intangible assets				4.5
Trade Names [Member] | K-Systems [Member]
Business Acquisition [Line Items]
Identifiable intangible assets					1
Trade Names [Member] | Genesis Genetics [Member]
Business Acquisition [Line Items]
Identifiable intangible assets						3.4
Trade Names [Member] | The Pipette Company [Member]
Business Acquisition [Line Items]
Identifiable intangible assets							0.4
Trade Names [Member] | Research Instruments [Member]
Business Acquisition [Line Items]
Identifiable intangible assets								2.2
Customer relationships | Grand Vista [Member]
Business Acquisition [Line Items]
Identifiable intangible assets	$ 14.9
Customer relationships | Wallace [Member]
Business Acquisition [Line Items]
Identifiable intangible assets		$ 2.5
Customer relationships | Reprogenetics UK [Member]
Business Acquisition [Line Items]
Identifiable intangible assets			$ 5.1
Customer relationships | Recombine [Member]
Business Acquisition [Line Items]
Identifiable intangible assets				$ 2.4
Customer relationships | K-Systems [Member]
Business Acquisition [Line Items]
Identifiable intangible assets					$ 0.8
Customer relationships | Genesis Genetics [Member]
Business Acquisition [Line Items]
Identifiable intangible assets						$ 25.2
Customer relationships | The Pipette Company [Member]
Business Acquisition [Line Items]
Identifiable intangible assets							$ 5.2
Customer relationships | Research Instruments [Member]
Business Acquisition [Line Items]
Identifiable intangible assets								$ 1.9

Restructuring and Integration33

Restructuring and Integration Costs (Narrative) (Details) - USD ($)	3 Months Ended	9 Months Ended	12 Months Ended
	Jul. 31, 2016	Jul. 31, 2016	Oct. 31, 2016	Jul. 31, 2017
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Activities, Completion Date			Oct. 31, 2016
Sauflon [Member]
Restructuring Cost and Reserve [Line Items]
Cumulative amounts incurred as of October 31, 2016			$ 148,300,000	$ 0
Additions during the period			56,600,000
Integration costs	$ 10,000,000
Sauflon [Member] | Product Rationalization
Restructuring Cost and Reserve [Line Items]
Cumulative amounts incurred as of October 31, 2016			129,400,000
Additions during the period			56,400,000
Sauflon [Member] | Product Rationalization | Cost of sales [Member]
Restructuring Cost and Reserve [Line Items]
Additions during the period	8,700,000	$ 23,500,000
Sauflon [Member] | Employee-related
Restructuring Cost and Reserve [Line Items]
Cumulative amounts incurred as of October 31, 2016			17,800,000
Additions during the period			0
Sauflon [Member] | Employee-related | Cost of sales [Member]
Restructuring Cost and Reserve [Line Items]
Additions during the period	$ 400,000	900,000
Sauflon [Member] | Employee-related | Selling, general and administrative expense [Member]
Restructuring Cost and Reserve [Line Items]
Additions during the period		100,000
Sauflon [Member] | Employee-related | Research and development expense [Member]
Restructuring Cost and Reserve [Line Items]
Additions during the period		100,000
Sauflon [Member] | Facilities-related
Restructuring Cost and Reserve [Line Items]
Cumulative amounts incurred as of October 31, 2016			1,100,000
Additions during the period			$ 200,000
Sauflon [Member] | Facilities-related | Selling, general and administrative expense [Member]
Restructuring Cost and Reserve [Line Items]
Additions during the period		$ 200,000

Restructuring and Integration34

Restructuring and Integration Costs (Details) - USD ($)	9 Months Ended	12 Months Ended
	Jul. 31, 2017	Oct. 31, 2016
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Activities, Completion Date		Oct. 31, 2016
Sauflon [Member]
Restructuring Cost and Reserve [Line Items]
Cumulative amounts incurred as of October 31, 2016	$ 0	$ 148,300,000
Restructuring Reserve [Roll Forward]
Balance, beginning	3,100,000	8,900,000
Additions (reductions) during the period		56,600,000
Payments during the period	(1,500,000)	(5,400,000)
Non-cash adjustments	(1,000,000)	(57,000,000)
Balance, ending	600,000	3,100,000
Sauflon [Member] | Employee-related
Restructuring Cost and Reserve [Line Items]
Cumulative amounts incurred as of October 31, 2016		17,800,000
Restructuring Reserve [Roll Forward]
Balance, beginning	2,800,000	8,600,000
Additions (reductions) during the period		0
Payments during the period	(1,500,000)	(5,200,000)
Non-cash adjustments	(700,000)	(600,000)
Balance, ending	600,000	2,800,000
Sauflon [Member] | Facilities-related
Restructuring Cost and Reserve [Line Items]
Cumulative amounts incurred as of October 31, 2016		1,100,000
Restructuring Reserve [Roll Forward]
Balance, beginning	300,000	300,000
Additions (reductions) during the period		200,000
Payments during the period	0	(200,000)
Non-cash adjustments	(300,000)	0
Balance, ending	0	300,000
Sauflon [Member] | Product Rationalization
Restructuring Cost and Reserve [Line Items]
Cumulative amounts incurred as of October 31, 2016		129,400,000
Restructuring Reserve [Roll Forward]
Balance, beginning	0	0
Additions (reductions) during the period		56,400,000
Payments during the period	0	0
Non-cash adjustments	0	(56,400,000)
Balance, ending	$ 0	$ 0

Inventories (Schedule of Invent

Inventories (Schedule of Inventories) (Details) - USD ($) $ in Millions	Jul. 31, 2017	Oct. 31, 2016
Inventory Disclosure [Abstract]
Raw materials	$ 104.7	$ 86
Work-in-process	15.1	12.6
Finished goods	334.1	319.1
Inventories, net	$ 453.9	$ 417.7

Intangible Assets (Schedule of

Intangible Assets (Schedule of Goodwill) (Details) - USD ($) $ in Millions	9 Months Ended	12 Months Ended
	Jul. 31, 2017	Oct. 31, 2016
Goodwill [Roll Forward]
Balance, beginning	$ 2,164.7	$ 2,197.1
Net additions during the nine months ended July 31, 2017	104.7	166
Translation	64.2	(198.4)
Balance, ending	2,333.6	2,164.7
CooperVision
Goodwill [Roll Forward]
Balance, beginning	1,646.4	1,827.6
Net additions during the nine months ended July 31, 2017	10.3	9.1
Translation	56.6	(190.3)
Balance, ending	1,713.3	1,646.4
CooperSurgical
Goodwill [Roll Forward]
Balance, beginning	518.3	369.5
Net additions during the nine months ended July 31, 2017	94.4	156.9
Translation	7.6	(8.1)
Balance, ending	$ 620.3	$ 518.3

Intangible Assets (Schedule o37

Intangible Assets (Schedule of Other Intangible Assets) (Details) - USD ($) $ in Millions	9 Months Ended
	Jul. 31, 2017	Oct. 31, 2016
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 843.4	$ 742.9
Accumulated Amortization & Translation	$ 355.5	301.8
Finite-Lived Intangible Asset, Useful Life	12 years
Other intangible assets, net	$ 487.9	441.1
Trademarks
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	40.7	36.6
Accumulated Amortization & Translation	$ 9.4	6.8
Finite-Lived Intangible Asset, Useful Life	12 years
Technology
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 423.5	354.8
Accumulated Amortization & Translation	$ 164.7	139.3
Finite-Lived Intangible Asset, Useful Life	11 years
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 310.3	285.7
Accumulated Amortization & Translation	$ 139.3	121.9
Finite-Lived Intangible Asset, Useful Life	13 years
License and distribution rights and other
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 68.9	65.8
Accumulated Amortization & Translation	$ 42.1	$ 33.8
Finite-Lived Intangible Asset, Useful Life	9 years

Intangible Assets (Narrative) (

Intangible Assets (Narrative) (Details)	9 Months Ended
	Jul. 31, 2017USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill, Impairment Loss	$ 0
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]
2,017	67,700,000
2,018	66,300,000
2,019	63,900,000
2,020	53,900,000
2,021	$ 52,400,000

Debt (Schedule of Debt) (Detail

Debt (Schedule of Debt) (Details) - USD ($) $ in Millions	Jul. 31, 2017	Oct. 31, 2016
Short-term:
Overdraft and other credit facilities	$ 33.4	$ 17.1
Current portion of long-term debt	0	210.7
Less unamortized debt issuance cost on term loans	0	(1.5)
Short-term debt	33.4	226.3
Long term:
Credit Agreement	354	0
Term loans	830	1,111.2
Other	0.2	0.2
Less unamortized debt issuance cost on term loans	(4.2)	(4)
Long-term debt	$ 1,180	$ 1,107.4

Debt (Narrative) (Details)

Debt (Narrative) (Details)	Apr. 30, 2017USD ($)	Mar. 01, 2016USD ($)	Aug. 04, 2014USD ($)	Sep. 12, 2013USD ($)	Jul. 31, 2017USD ($)	Jul. 31, 2017USD ($)	Oct. 31, 2016USD ($)
Line of Credit Facility [Line Items]
Term loans					$ 830,000,000	$ 830,000,000	$ 1,111,200,000
Required minimum Interest coverage ratio						3
Required maximum total leverage ratio						3.75
Interest coverage ratio					24.08	24.08
Total leverage ratio					1.70	1.70
Amount available under the credit agreement					$ 645,700,000	$ 645,700,000
Minimum [Member]
Line of Credit Facility [Line Items]
Commitment fee percentage		0.125%
Maximum [Member]
Line of Credit Facility [Line Items]
Commitment fee percentage		0.25%
2016 Credit Agreement [Member]
Line of Credit Facility [Line Items]
Line of credit facility, potential additional borrowing capacity		$ 750,000,000
Revolving Credit Facility [Member]
Line of Credit Facility [Line Items]
Aggregate commitment amount of credit facility		$ 1,000,000,000
2016 Credit Agreement [Member]
Line of Credit Facility [Line Items]
Line of credit facility, initiation date		Mar. 1, 2016
Term loans		$ 830,000,000			830,000,000	830,000,000
Line of credit facility interest rate margin on base rate loans percentage		1.00%
Line of credit facility interest rate margin on foreign currency loans percentage		1.75%
2016 Credit Agreement [Member] | Federal Funds Rate [Member]
Line of Credit Facility [Line Items]
Debt instrument, basis spread on variable rate		0.00%
2016 Credit Agreement [Member] | Eurodollar [Member]
Line of Credit Facility [Line Items]
Debt instrument, basis spread on variable rate		0.75%
Line of Credit [Member]
Line of Credit Facility [Line Items]
Debt instrument, maturity date		Mar. 1, 2021
Term Loan $700M [Member]
Line of Credit Facility [Line Items]
Term loans			$ 700,000,000		0	0
Debt instrument, maturity date			Aug. 4, 2017
Debt Instrument, Issuance Date			Aug. 4, 2014
Debt term			3 years
Repayments of Debt	$ 207,000,000						493,000,000
Term Loan $300M [Member]
Line of Credit Facility [Line Items]
Term loans				$ 300,000,000	0	$ 0
Debt instrument, maturity date				Sep. 12, 2018
Debt Instrument, Issuance Date				Sep. 12, 2013
Debt term				5 years
Repayments of Debt					$ 285,000,000		$ 15,000,000
Amortization of term loan principal				5.00%
Debt instrument, date of first required payment				Oct. 31, 2016
Medium-term Notes [Member] | Minimum [Member]
Line of Credit Facility [Line Items]
Debt instrument, basis spread on variable rate						0.00%
Medium-term Notes [Member] | Maximum [Member]
Line of Credit Facility [Line Items]
Debt instrument, basis spread on variable rate						0.50%
Medium-term Notes [Member] | London Interbank Offered Rate (LIBOR) [Member] | Minimum [Member]
Line of Credit Facility [Line Items]
Debt instrument, basis spread on variable rate						0.75%
Medium-term Notes [Member] | London Interbank Offered Rate (LIBOR) [Member] | Maximum [Member]
Line of Credit Facility [Line Items]
Debt instrument, basis spread on variable rate						1.50%

Income Taxes (Narrative) (Detai

Income Taxes (Narrative) (Details) - USD ($) $ in Millions	9 Months Ended
	Jul. 31, 2017	Jul. 31, 2016	Nov. 01, 2016
Components of Income Tax Expense (Benefit), Continuing Operations [Abstract]
Effective tax rate (ETR)	4.40%	5.40%
Unrecognized tax benefits			$ 39.9
Unrecognized tax benefits that would impact ETR			29.7
Interest and penalties			3.7
Unrecognized tax benefits related to tax positions			$ 1.6

Earnings Per Share (Schedule of

Earnings Per Share (Schedule of Earnings Per Share) (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Jul. 31, 2017	Jul. 31, 2016	Jul. 31, 2017	Jul. 31, 2016
Earnings Per Share [Abstract]
Net income attributable to Cooper stockholders	$ 103,600	$ 87,900	$ 284,300	$ 213,400
Basic:
Weighted average common shares	48,900	48,600	48,900	48,400
Basic earnings per common share attributable to Cooper stockholders	$ 2.12	$ 1.81	$ 5.81	$ 4.41
Diluted:
Effect of potential dilutive common shares	700	400	600	500
Diluted weighted average common shares	49,600	49,000	49,500	48,900
Diluted earnings per common share attributable to Cooper stockholders	$ 2.09	$ 1.79	$ 5.74	$ 4.36

Earnings Per Share (Schedule 43

Earnings Per Share (Schedule of Stock Options to Purchase Common Stock Not Included in Diluted Net Income Per Share Calculation) (Details) - $ / shares shares in Thousands	3 Months Ended		9 Months Ended
	Jul. 31, 2017	Jul. 31, 2016	Jul. 31, 2017	Jul. 31, 2016
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Numbers of stock option shares excluded	0	49	192	418
Range of exercise prices, lower limit	$ 0	$ 162.28	$ 175.31	$ 131.6
Range of exercise prices, upper limit	$ 0	$ 162.28	$ 175.31	$ 162.69
Restricted Stock Units (RSUs) [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Numbers of stock option shares excluded	2	1	3	3

Share-Based Compensation Plan44

Share-Based Compensation Plans (Schedule Of Compensation Expense And Related Income Tax Benefit For Share-Based Awards) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Jul. 31, 2017	Jul. 31, 2016	Jul. 31, 2017	Jul. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total share-based compensation expense	$ 7.9	$ 7.4	$ 27.7	$ 21.9
Related income tax benefit	2.6	2.2	8.5	6.5
Adjustment to cost of sales for capitalized inventory	0.9
Selling, general and administrative expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense	7.7	6.4	24.9	19.2
Cost of sales [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense	(0.1)	0.7	1.9	1.8
Research and development expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense	0.3	0.3	0.9	0.9
Capitalized in inventory [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense	$ 0.8	$ 0.7	$ 2.8	$ 1.8

Stockholders' Equity (Schedule

Stockholders' Equity (Schedule of Changes in Accumulated Other Comprehensive Income (Loss))(Details) - USD ($) $ in Millions	9 Months Ended	12 Months Ended
	Jul. 31, 2017	Oct. 31, 2016
Foreign Currency Translation Adjustment [Roll Forward]
Foreign Currency Translation Adjustment, Beginning Balance	$ (461.4)	$ (171.8)
Foreign Currency Translation Adjustment, Gross change in value for the period	104.8	(289.6)
Foreign Currency Translation Adjustment, Tax effect for the period		0
Foreign Currency Translation Adjustment, Ending Balance	(356.6)	(461.4)
Minimum Pension Liability [Roll Forward]
Minimum Pension Liability, Beginning Balance	(28.2)	(19.8)
Minimum Pension Liability, Gross change in value for the period	0	(13.7)
Minimum Pension Liability, Tax effect for the period		5.3
Minimum Pension Liability, Ending Balance	(28.2)	(28.2)
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Total, Beginning balance	(489.6)	(191.6)
Gross change in value for the period	104.8	(303.3)
Tax effect for the period		5.3
Total, Ending balance	$ (384.8)	$ (489.6)

Stockholders' Equity (Share Rep

Stockholders' Equity (Share Repurchases) (Details) - USD ($)	3 Months Ended	9 Months Ended
	Apr. 30, 2017	Jul. 31, 2017	Jul. 31, 2016	Mar. 21, 2017	Dec. 15, 2011
Equity [Abstract]
Share Repurchase Program, maximum amount authorized				$ 1,000,000,000	$ 500,000,000
Number of common stock repurchased, shares	150,000	0	0
Treasury Stock, Value, Acquired, Cost Method	$ 29,500,000
Accelerated Share Repurchases, Final Price Paid Per Share	$ 196.82
Share Repurchase Program, remaining authorized amount		$ 589,000,000

Stockholders' Equity (Dividends

Stockholders' Equity (Dividends) (Details) - USD ($) $ / shares in Units, $ in Millions	Aug. 03, 2017	Feb. 09, 2017	Apr. 30, 2017	Jul. 31, 2017	Jul. 31, 2016
Subsequent Event [Line Items]
Dividends on common stock		$ 1.5		$ 1.5	$ 1.5
Cash dividend, per share		$ 0.03
Dividends payable, date of record			Jan. 23, 2017	Jul. 21, 2017
Subsequent Event [Member]
Subsequent Event [Line Items]
Dividends on common stock	$ 1.5
Cash dividend, per share	$ 0.03

Employee Benefits (Schedule of

Employee Benefits (Schedule of Components of Net Periodic Pension Costs) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Jul. 31, 2017	Jul. 31, 2016	Jul. 31, 2017	Jul. 31, 2016
General Discussion of Pension and Other Postretirement Benefits [Abstract]
Service cost	$ 2.5	$ 2.3	$ 7.5	$ 6.9
Interest cost	1.1	1.2	3.3	3.7
Expected return on plan assets	(1.8)	(1.6)	(5.4)	(4.9)
Recognized net actuarial loss	0.7	0.4	2.1	1.2
Net periodic pension cost	$ 2.5	$ 2.3	$ 7.5	$ 6.9

Employee Benefits (Narrative) (

Employee Benefits (Narrative) (Details) - USD ($) $ in Millions	9 Months Ended
	Jul. 31, 2017	Jul. 31, 2016
General Discussion of Pension and Other Postretirement Benefits [Abstract]
Company's contribution to the pension plan	$ 5	$ 5
Defined benefit plan, estimated future employer contributions in current fiscal year	$ 5
Expected rate of return on plan assets for determining net periodic pension cost	8.00%

Contingencies (Details)

Contingencies (Details) $ in Millions	26 Months Ended
	Apr. 30, 2017action	Jul. 31, 2017USD ($)
Commitments and Contingencies Disclosure [Abstract]
Number of putative class action complaints filed (over) | action	50
Litigation Settlement, Amount | $		$ 3

Business Segment Information (S

Business Segment Information (Schedule of Segment Information) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Jul. 31, 2017	Jul. 31, 2016	Jul. 31, 2017	Jul. 31, 2016
Segment Reporting Information [Line Items]
Net sales	$ 556,000	$ 514,700	$ 1,577,500	$ 1,448,200
Operating income (loss)	112,800	102,700	320,600	249,900
Interest expense	8,300	8,000	23,300	20,900
Other (income) expense, net	(3,200)	1,300	(100)	2,200
Income before income taxes	107,700	93,400	297,400	226,800
CooperVision
Segment Reporting Information [Line Items]
Net sales	437,300	409,900	1,235,000	1,165,500
Operating income (loss)	109,500	99,400	308,900	235,700
CooperSurgical
Segment Reporting Information [Line Items]
Net sales	118,700	104,800	342,500	282,700
Operating income (loss)	14,900	14,700	48,200	47,900
Corporate
Segment Reporting Information [Line Items]
Operating income (loss)	(11,600)	(11,400)	(36,500)	(33,700)
Toric lens | CooperVision
Segment Reporting Information [Line Items]
Net sales	138,300	126,100	390,800	354,100
Multifocal lens | CooperVision
Segment Reporting Information [Line Items]
Net sales	46,800	44,300	132,100	127,200
Single-use sphere lens | CooperVision
Segment Reporting Information [Line Items]
Net sales	115,800	104,300	319,500	292,700
Non single-use sphere and other | CooperVision
Segment Reporting Information [Line Items]
Net sales	$ 136,400	$ 135,200	$ 392,600	$ 391,500

Business Segment Information 52

Business Segment Information (Schedule of Identifiable Assets By Segment Information) (Details) - USD ($) $ in Millions	Jul. 31, 2017	Oct. 31, 2016
Segment Reporting Information [Line Items]
Total Identifiable assets	$ 4,782.8	$ 4,478.6
CooperVision
Segment Reporting Information [Line Items]
Total Identifiable assets	3,515.8	3,382.4
CooperSurgical
Segment Reporting Information [Line Items]
Total Identifiable assets	1,116.2	907.1
Corporate
Segment Reporting Information [Line Items]
Total Identifiable assets	$ 150.8	$ 189.1

Business Segment Information 53

Business Segment Information (Schedule of Net Sales To External Customers By Country Of Domicile) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Jul. 31, 2017	Jul. 31, 2016	Jul. 31, 2017	Jul. 31, 2016
Segment Reporting Information [Line Items]
Total net sales to external customers	$ 556,000	$ 514,700	$ 1,577,500	$ 1,448,200
United States
Segment Reporting Information [Line Items]
Total net sales to external customers	235,300	227,800	694,800	656,000
Europe
Segment Reporting Information [Line Items]
Total net sales to external customers	200,600	182,800	544,500	505,800
Rest of world
Segment Reporting Information [Line Items]
Total net sales to external customers	$ 120,100	$ 104,100	$ 338,200	$ 286,400

Business Segment Information 54

Business Segment Information (Schedule of Long-Lived Assets By Country Of Domicile) (Details) - USD ($) $ in Millions	Jul. 31, 2017	Oct. 31, 2016
Segment Reporting Information [Line Items]
Total long-lived assets	$ 894.9	$ 877.7
United States
Segment Reporting Information [Line Items]
Total long-lived assets	467.7	464.1
Europe
Segment Reporting Information [Line Items]
Total long-lived assets	345.4	334.4
Rest of world
Segment Reporting Information [Line Items]
Total long-lived assets	$ 81.8	$ 79.2